Alnylam Replaces Sanofi Partnership With Second Regeneron Tie-Up For RNAi Drugs
Already partnered with Regeneron in NASH, Alnylam unveils a new R&D collaboration in eye, CNS and liver indications, after Alnylam and Sanofi end the research phase of their relationship.
You may also be interested in...
Alnylam has unveiled Phase I data showing its RNAi candidate can eliminate the amyloid precursor protein in the brain – opening the door to treating Alzheimer’s and many more CNS diseases.
First clinical demonstration of gene silencing in the brain using an RNAi therapeutic could have implications for diseases like Alzheimer’s, ALS and Parkinson’s disease.
Senior VP-global clinical development David Weinreich addresses the company's growing investment in oncology drug development, why Regeneron is well positioned to lead in the area, and business development.